Abbott Laboratories (NYSE:ABT) Receives Average Rating of "Moderate Buy" from Analysts

Key Points

• Analysts: "Moderate Buy" — 26 brokers cover Abbott with an average recommendation of "Moderate Buy" (19 buys, 5 holds, 2 strong buys) and a 1‑year average price target of about $119.43.
• Earnings and guidance — Abbott topped Q1 estimates with $1.15 EPS and $11.16B revenue (vs. $1.14 and $10.99B) and set FY2026 guidance of $5.38–$5.58 EPS (consensus ~$5.48).
• Dividend and insider activity — The company declared a $0.63 quarterly dividend (annualized $2.52, ~2.8% yield, ~70.6% payout ratio), and insiders were net buyers recently, including the CFO purchasing 2,200 shares at $91.50.

Abbott Laboratories (NYSE:ABT - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the twenty-six brokerages that are presently covering the firm, MarketBeat reports. Five analysts have rated the stock with a hold recommendation, nineteen have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $119.4348.

ABT has been the subject of several research analyst reports. JPMorgan Chase & Co. cut their price objective on Abbott Laboratories from $123.00 to $110.00 and set an "overweight" rating for the company in a report on Friday, April 17th. Leerink Partners cut their price objective on Abbott Laboratories from $119.00 to $106.00 and set a "market perform" rating for the company in a report on Tuesday, April 21st. The Goldman Sachs Group cut their price objective on Abbott Laboratories from $140.00 to $121.00 and set a "buy" rating for the company in a report on Wednesday, April 8th. Raymond James Financial cut their price objective on Abbott Laboratories from $130.00 to $115.00 and set an "outperform" rating for the company in a report on Friday, April 17th. Finally, BTIG Research reaffirmed a "buy" rating and issued a $131.00 price objective on shares of Abbott Laboratories in a report on Monday, April 27th.

Abbott Laboratories Stock Up 0.1%

Abbott Laboratories stock opened at $89.51 on Monday. The firm has a market cap of $155.91 billion, a price-to-earnings ratio of 25.07, a PEG ratio of 1.49 and a beta of 0.65. The stock has a fifty day simple moving average of $104.33 and a two-hundred day simple moving average of $115.97. Abbott Laboratories has a 12 month low of $89.14 and a 12 month high of $139.06. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56.

Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, topping analysts' consensus estimates of $1.14 by $0.01. The business had revenue of $11.16 billion during the quarter, compared to analyst estimates of $10.99 billion. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The company's quarterly revenue was up 7.8% compared to the same quarter last year. During the same quarter last year, the company earned $1.09 EPS. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Equities analysts predict that Abbott Laboratories will post 5.48 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be issued a $0.63 dividend. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.8%. Abbott Laboratories's payout ratio is presently 70.59%.

Insider Buying and Selling

In related news, CFO Philip P. Boudreau bought 2,200 shares of the stock in a transaction that occurred on Thursday, April 23rd. The shares were bought at an average cost of $91.50 per share, for a total transaction of $201,300.00. Following the completion of the transaction, the chief financial officer owned 2,200 shares of the company's stock, valued at approximately $201,300. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Mary K. Moreland sold 613 shares of Abbott Laboratories stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $70,850.54. Following the transaction, the executive vice president owned 104,291 shares in the company, valued at $12,053,953.78. This trade represents a 0.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have purchased 22,200 shares of company stock valued at $2,215,100 and have sold 3,055 shares valued at $353,097. 0.46% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Abbott Laboratories

Institutional investors and hedge funds have recently bought and sold shares of the stock. MidAtlantic Capital Management Inc. purchased a new position in Abbott Laboratories during the fourth quarter valued at $25,000. Cornerstone Financial Management LLC purchased a new position in Abbott Laboratories during the fourth quarter valued at $25,000. Purpose Unlimited Inc. purchased a new position in Abbott Laboratories during the fourth quarter valued at $25,000. Portfolio Resources Advisor Group Inc. purchased a new position in Abbott Laboratories during the fourth quarter valued at $26,000. Finally, Abound Financial LLC purchased a new position in Abbott Laboratories during the fourth quarter valued at $26,000. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.